U
AVDL

UBS’s Avadel Pharmaceuticals AVDL Stock Holding History

UBS’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		$14K Buy
+1,000
New +$14.4K ﹤0.01% 8429
2014
Q2 		– Sell
-5,000
Closed -$67K – 10398
2014
Q1 		$67K Buy
+5,000
New +$53.6K ﹤0.01% 6463

Other funds holding AVDL

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
CCP
Clough Capital Partners Boston, Massachusetts $1.04B AUM 49.7% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

UBS's AVDL Position: Q3 2014 in Review

UBS reduced its Avadel Pharmaceuticals (AVDL) stake by 1.3% in Q3 2014, selling an estimated $10.4K and leaving 54,174 shares worth $775K. The position accounts for ﹤0.01% of the portfolio, ranked #3835.

UBS first reported a position in AVDL in Q2 2013 and has held it in 6 quarters since. The position peaked at $947K in Q1 2014. 71 funds tracked by Wall St. Rank hold AVDL as of Q3 2014.

  • UBS held 54,174 shares of Avadel Pharmaceuticals worth $775K as of Q3 2014.
  • UBS sold 721 Avadel Pharmaceuticals shares in Q3 2014, an estimated $10.4K.
  • Avadel Pharmaceuticals made up ﹤0.01% of UBS's portfolio in Q3 2014, its #3835 holding.
  • UBS first reported a position in Avadel Pharmaceuticals in Q2 2013 and has held it in 6 quarters since.
  • UBS's Avadel Pharmaceuticals position peaked at $947K in Q1 2014.
  • 71 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.